Hot Mandates: Boston-Based VC

A Boston area-based venture firm specializes in early stage opportunities in med-tech, diagnostics, and instruments. Currently, the firm has a total AUM of $125 million. Typically, the firm initially invests in a start-up at the early stage, but reserves capital for participation later on. The firm typically makes a first investment in the range of $1-3 million, but is open to making larger or smaller allocations as opportunities arise. The firm expects to invest a total in the range of $7-12 million in a given portfolio company as it makes progress toward a successful exit. The firm prefers to act as a lead investor for early stage deals.

The firm is most interested in companies developing medical devices, diagnostics tools and instrumentation. The firm is looking for companies targeting global unmet clinical needs in areas such as oncology, cardiovascular disease, obesity, and women’s health. The firm is willing to invest in companies that are pre-prototype as well as those that have a working prototype of their product.

The firm looks to act as a long term strategic partner with its portfolio companies. The firm looks for experienced management teams and generally looks to take a board seat into companies.

If you are interested in more information about this investor and other investors tracked by LSN, please email LHI@lifesciencenation.com.

Investor-Panelists at Digital RESI June

By Karen Deyo, Director of Investor Research, Israel BD, LSN

The Life Science Nation (LSN) team has already gathered an exciting lineup of panelists for our Digital Redefining Early Stage Investments (RESI) conference, taking place June 8-10. Whether from organizations that have contributed to RESI in the past, or those speaking for the first time, panelists will contribute dynamic conversations and provide useful tips for fundraising startups. Here is a spotlight on some of the speakers who will be joining us in June!

Faz Bashi
Member of BOD
Life Science Angels
Anna Turetsky
Principal, Venture Investments
The Mark Foundation for Cancer Research
Juan Cueva
Senior Associate
Action Potential Venture Capital
Miles Gerson
Partner
Takeda Ventures
Sam Goldberger
Partner
Ambit Health Ventures
Brian Meshkin
Managing Partner, Profound Ventures
Partner, Cancer Fund
John Parker
Founder & Managing Director
Springhood Impact Ventures
Richard Proscia
Senior Associate
Providence Ventures
Yaniv Sneor
Founding Member
Mid Atlantic Bio Angels

Register by May 7 to save $50 and hear from these panelists and to schedule meetings with the below investors who are participating in RESI!

Confirmed Digital RESI June Investors and Strategic Partners*

*April 15, 2021

Patents, Profiles, Patience, and the Power of a Good “No”: The Panaceutics Rx Story

By Rory McCann, Marketing Manager & Conference Producer, LSN

Panaceutics Rx is an early-stage company advancing accessible personalized medicine based on patients’ digital health profiles using robotic platforms and patented processes.

We spoke with Panaceutics CEO, Edison Hudson about the need for more accessible adherence to life-saving therapies and Panaceutics’ approach to working with hospitals, investors, and physicians.

Panaceutics Rx is an Innovator’s Pitch Challenge winner at last month’s Longevity, Health & Innovation, a Redefining Early Stage Investments (RESI) partnering event. Learn more about RESI and sign up by May 7 to save $50 on early bird rates.

Fundraising for Digital Health: An Investor’s Perspective

By Caitlin Dolegowski, Marketing Specialist, LSN

CaitiThe impact of the COVID-19 pandemic will be lasting – creating both opportunities and challenges in the digital health sector. At last month’s Healthtech Partnering Week, these were popular themes throughout investor panels across the three early-stage partnering events, Digital RESI March, 4D Meets AI, and Longevity, Health & Innovation.

A main theme from investors participating in these panels is the sheer enormity of the opportunities in digital health. Dr. Stephen Pitt, Head of JLabs US North East kicked off the 4D Meets AI Digital Health panel by saying, “2020 was certainly a turning point for digital health. I think we saw the pandemic help accelerate some areas, such as telehealth.” The Digital Health for the Elderly panel at Longevity, Health & Innovation reiterated Dr. Pitt’s statement through a conversation surrounding the needs for access to high-quality telehealth services for seniors. This point was furthered in Digital RESI March’s panel by Relentless Venture Fund’s Managing Partner, Brenda Irwin, who stated, “$14.1B was deployed in digital health in 2020, which was a 72% increase from the most active year, which was 2018.” Additionally, major players like Microsoft are advancing the need for digital health advancements through their recent acquisition of AI and tech company, Nuance Communications for $16B.

Early-stage entrepreneurs are in a prime moment of investment opportunity. Some of the pre-pandemic emerging digital health ideas are now the new normal and the industry is at the tip of the iceberg of innovation. Health Equity Capital Managing Partner, Taja Lester highlighted a virtual healthtech advancement where 3,500 Parkinson’s patients participated in a clinical trial conducted by the National Institute of Aging entirely from patients’ homes. Additionally, technology is advancing; smart phones, wearables, tablets, etc. can now provide biomarkers remotely. This also contributes to provider interoperability, which allows for an entire care team to have access to all the information specific to them in one location. These improvements have been “drastically accelerated and made necessary by COVID,” according to Justin Kelly, Associate at AXA Venture Partners.

Functional versus personable partnering is also an undercurrent highlighted by digital access. In-person relationship-building can never be fully replaced with these remote technological advancements. “I think the personal connection is a very important part of how you find an early investor and how you get somebody on board that sees the problem the way you do because you have something really strong in common to go through the different phases that a start-up goes through,” says Syllable Co-Founder and CEO, Kobus Jooste.

With the rise of COVID-19 vaccinations, in-person events may be on the horizon. Whether partnering continues virtually or through a hybrid or in-person model, the applications of digital health advancement are likely here to stay, and will continue creating value for patients, providers, and partnerships. If you’re ready to dive into match-based partnering that fits your product and stage of development, register for Digital RESI, June 8-10 at early bird rates until May 7.

Hot Investor Mandate: Family Office Advisory Firm Seeks Direct Investment Opportunities Across All Life Science Sectors, Allocating Up to $25M

A registered investment consultancy firm is involved with independent advisory, outsourced CIO, and direct investments. The firm acts as the consultant role to advise global family offices with their investment objectives. The firm is looking for investment leads in early-stage life science industry. Companies who are looking to raise their series B – series C rounds would be in their sweet spot. The firm typically invests in $1M-25M, which depends on the stage of development.

The firm is also open to looking at earlier stage companies but the investment size might vary. The firm is looking for companies in the US (60%), China (20%), UK, Germany, India, and other countries with emerging life science technologies.

The firm is opportunistic in sectors and is willing to consider any indications.

The firm has no specific requirements for companies. The firm might take an observer seat or board seat in applicable cases.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: PE Firm Invests $5-10M in Global Companies with Market Opportunities in China

A PE firm based in China manages 2 active funds – the RMB and USD Funds – that focus on investments in the life science space. The RMB Fund invests $5-40 M in companies based in China, and the USD Fund invests $5-10 M in companies of all parts of the world, with a focus in US and China. With these funds, the firm will make 1-2 investments per year in companies that have market opportunities in China. The firm will provide companies with resources and expertise for competitive market entry and will assist pre-market products with commercialization.

The firm is opportunistic and is open to all life science sectors in all indications, including therapeutics, medical technology, diagnostics, and digital health. In therapeutics, the firm will consider products that are in Phase II clinical trials and beyond, but may consider companies with pre-clinical or early clinical assets if they demonstrate high potential. In the medical technology sector, the firm will support devices of all regulatory pathways and will also assist with CFDA regulatory filing and approval. These devices are expected to be undergoing pivotal trials at the earliest, and should be close to commercialization.

The firm will invest only in companies that are looking to enter the market in China, and is willing to both lead and co-invest. The companies will ideally have an IPO or trade sale runway of 6 to 24 months. Companies should be backed by an experienced management team but for companies based in China, the firm can assist with the assembly of a complete management team.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: USA-Based Family Office Actively Invests in Medical Technology & Consumer Health Companies Across the Globe

A family office behind a large industrial engineering firm invests in and incubates new technologies in the medical device and consumer health sectors. The firm is invests directly into early stage companies, focusing on opportunities in which the firm’s engineering and commercialization expertise can provide a value-add. The firm’s investments may include equity financing, services such as prototyping and design, and other structures such as royalties. The firm invests worldwide.

The firm focuses on medical technology and consumer health, including devices, diagnostics, sterilization, blood testing, sensors, MRI/Radiation machines, and home health products. The firm is a multi-stage investor, and has worked with entrepreneurs as early as idea-stage. The firm invests in all classes of medical device including PMA opportunities. Hardware only.  No pure software, biotech/drugs/medication or services businesses.

The firm is focused on investing in companies in which the firm’s expertise is a relevant value-add.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.